Scientists Found a Dangerous Hospital Superbug Is Learning to Resist One of Our Last-Resort Antibiotics

A powerful last-line antibiotic combination used to treat some of the most dangerous hospital infections may be becoming less effective against Pseudomonas aeruginosa, one of the world's most difficult-to-treat bacteria. Researchers have identified genetic mutations that allow the pathogen to weaken the effects of ceftazidime-avibactam, raising new concerns about the continued spread of antibiotic resistance.

The study, published in Microbiology Spectrum, examined bacterial samples from two critically ill patients in China who were infected with P. aeruginosa. The researchers identified previously unrecognized genetic changes that enabled the bacteria to resist one of the few remaining antibiotics available for carbapenem-resistant infections.

A Persistent Hospital Threat

Pseudomonas aeruginosa is an opportunistic bacterium that primarily threatens people with weakened immune systems, particularly patients receiving intensive care.

It can colonize ventilators, urinary catheters, and other medical devices, making it a common cause of healthcare-associated bloodstream, lung, urinary tract, and wound infections.

Many strains have already evolved resistance to carbapenems, a class of antibiotics often reserved for severe infections when other treatments fail.

To combat these multidrug-resistant bacteria, clinicians increasingly rely on ceftazidime-avibactam, a combination therapy designed to overcome bacterial resistance mechanisms that render many older antibiotics ineffective.

How the Bacteria Became Resistant

The researchers discovered that bacterial samples from the two patients contained altered forms of enzymes known as KPC-71 and KPC-78.

These enzymes belong to a group of carbapenemases that normally help bacteria destroy certain antibiotics before the drugs can act.

Laboratory testing showed that the newly identified enzyme variants significantly reduced the effectiveness of ceftazidime-avibactam.

The mutations appeared to interfere with avibactam—the component specifically designed to block these bacterial enzymes—allowing the bacteria to once again inactivate the antibiotic combination.

As a result, one of the most important treatments for carbapenem-resistant P. aeruginosa became substantially less effective.

Resistance Came With an Unexpected Cost

The researchers also observed an intriguing trade-off.

Although the bacterial strains became more resistant to ceftazidime-avibactam, they simultaneously became more susceptible to older carbapenem antibiotics, including imipenem and meropenem.

This phenomenon, sometimes referred to as a "see-saw effect," suggests that developing resistance to one antibiotic may temporarily reduce resistance to another.

According to the researchers, this could create a short-term opportunity for clinicians to use carbapenems against bacteria that had previously become resistant to them.

However, they caution that this advantage may prove temporary.

Once carbapenem treatment resumes, the bacteria may continue evolving, potentially regaining carbapenem resistance while maintaining reduced susceptibility to ceftazidime-avibactam.

For this reason, the researchers emphasize that any apparent return of carbapenem susceptibility should be interpreted carefully and monitored closely during treatment.

Why These Findings Matter

Although P. aeruginosa is commonly found in soil, water, and moist environments, it usually poses little risk to healthy individuals.

For hospitalized patients, however, particularly those with weakened immune systems or invasive medical devices, the bacterium can cause life-threatening infections that are increasingly difficult to treat.

The bacterial lineage examined in this study, known as ST463, has already attracted attention in China because of its ability to spread efficiently, cause severe disease, and resist multiple classes of antibiotics.

The emergence of ceftazidime-avibactam resistance within this lineage raises additional concerns about the longevity of one of medicine's most valuable last-line treatments.

The findings also illustrate how rapidly bacteria can adapt, even to relatively new antibiotics that were specifically developed to overcome existing resistance mechanisms.

The Growing Challenge of Antimicrobial Resistance

The researchers say their findings reinforce the importance of antibiotic stewardship, infection prevention, and routine surveillance for emerging resistance.

Early identification of resistant bacterial strains allows clinicians to adjust treatment before resistance becomes widespread or outbreaks occur.

The World Health Organization has identified multidrug-resistant P. aeruginosa as one of the world's highest-priority bacterial pathogens because of its increasing resistance and the limited number of effective treatment options.

Researchers worldwide continue to investigate new antibiotics alongside alternative approaches, including bacteriophage therapy and carefully designed combination treatments, in an effort to stay ahead of rapidly evolving bacteria.

At the same time, preventing hospital-acquired infections through rigorous hygiene practices, careful management of invasive medical devices, and responsible antibiotic use remains one of the most effective strategies for slowing the spread of antimicrobial resistance.

The authors conclude that patients receiving ceftazidime-avibactam—particularly those infected with ST463 strains—should be monitored closely throughout treatment. Continuous genetic and antibiotic susceptibility testing, they argue, will be essential for detecting resistance early and preserving the effectiveness of the shrinking arsenal of antibiotics available against dangerous hospital superbugs.